EPO and Huntington disease: 362 adult HD patients from 16 European dialysis centers entered the study with half of the patients receiving r-HuEPO during the first year (first phase) of the trial and then serving as the control group during the second year (second phase) and the other half followed the opposite treatment plan. These patients were monitored for the drug safety of SC administered EPO. A total of 73 patients dropped out from the study.